Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
MACROGENICS INC (MGNX)
|
Add to portfolio |
|
|
|
| Price: |
$16.90
| | Metrics |
| OS: |
61.9
|
M
| |
|
|
| Market cap: |
$1.05
|
B
| |
|
|
|
Net cash:
|
$109
|
M
| |
$1.76
|
per share
|
|
EV:
|
$938
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-05-19 | Dec-31-18 | Dec-05-18 | Dec-31-17 |
| Revenues | 151.9 | 77.4 | 104.9 | 64.2 | 64.2 | 60.1 | 60.1 | 157.7 |
| Revenue growth | 96.2% | -26.2% | 63.4% | 6.8% | 6.8% | -61.9% | -61.9% | 71.7% |
| Cost of goods sold | 3.4 | 2.7 | 0.0 | 0.0 | 195.3 | 0.0 | 190.8 | 0.0 |
| Gross profit | 148.6 | 74.8 | 104.9 | 64.2 | -131.1 | 60.1 | -130.7 | 157.7 |
| Gross margin | 97.8% | 96.6% | 100.0% | 100.0% | -204.3% | 100.0% | -217.4% | 100.0% |
| Research and development | 207.0 | 214.6 | 193.2 | 195.3 | | 190.8 | | 147.2 |
| General and administrative | 58.9 | 63.0 | 42.7 | 46.1 | 46.1 | 40.5 | 40.5 | 32.7 |
| EBIT | -121.4 | -202.8 | -131.1 | -177.2 | -177.2 | -171.2 | -171.2 | -22.1 |
| EBIT margin | -79.9% | -261.9% | -125.0% | -276.0% | -276.0% | -284.8% | -284.8% | -14.0% |
| Pre-tax income | -119.8 | -202.1 | -129.7 | -151.8 | -151.8 | -171.5 | -171.5 | -19.6 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -119.8 | -202.1 | -129.7 | -151.8 | -151.8 | -171.5 | -171.5 | -19.6 |
| Net margin | -78.8% | -261.0% | -123.7% | -236.5% | -236.5% | -285.2% | -285.2% | -12.4% |
| |
| Diluted EPS | ($1.95) | ($3.37) | ($2.47) | ($3.16) | ($3.16) | ($4.19) | ($4.19) | ($0.54) |
| Shares outstanding (diluted) | 61.4 | 59.9 | 52.4 | 48.1 | 48.1 | 40.9 | 40.9 | 36.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|